Traditionally, endocrine therapy, including aromatase inhibitors (AI) or fulvestrant, is recommended as first-line treatment for HR+/HER2- BC patients, unless there is a visceral crisis or life-threatening situation [8, 9]. Here, ERBB2 is linked to breast cancer.